Literature DB >> 25694601

Adenovirus replaces mitotic checkpoint controls.

Roberta L Turner1, Peter Groitl2, Thomas Dobner2, David A Ornelles3.   

Abstract

UNLABELLED: Infection with adenovirus triggers the cellular DNA damage response, elements of which include cell death and cell cycle arrest. Early adenoviral proteins, including the E1B-55K and E4orf3 proteins, inhibit signaling in response to DNA damage. A fraction of cells infected with an adenovirus mutant unable to express the E1B-55K and E4orf3 genes appeared to arrest in a mitotic-like state. Cells infected early in G1 of the cell cycle were predisposed to arrest in this state at late times of infection. This arrested state, which displays hallmarks of mitotic catastrophe, was prevented by expression of either the E1B-55K or the E4orf3 genes. However, E1B-55K mutant virus-infected cells became trapped in a mitotic-like state in the presence of the microtubule poison colcemid, suggesting that the two viral proteins restrict entry into mitosis or facilitate exit from mitosis in order to prevent infected cells from arresting in mitosis. The E1B-55K protein appeared to prevent inappropriate entry into mitosis through its interaction with the cellular tumor suppressor protein p53. The E4orf3 protein facilitated exit from mitosis by possibly mislocalizing and functionally inactivating cyclin B1. When expressed in noninfected cells, E4orf3 overcame the mitotic arrest caused by the degradation-resistant R42A cyclin B1 variant. IMPORTANCE: Cells that are infected with adenovirus type 5 early in G1 of the cell cycle are predisposed to arrest in a mitotic-like state in a p53-dependent manner. The adenoviral E1B-55K protein prevents entry into mitosis. This newly described activity for the E1B-55K protein appears to depend on the interaction between the E1B-55K protein and the tumor suppressor p53. The adenoviral E4orf3 protein facilitates exit from mitosis, possibly by altering the intracellular distribution of cyclin B1. By preventing entry into mitosis and by promoting exit from mitosis, these adenoviral proteins act to prevent the infected cell from arresting in a mitotic-like state.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25694601      PMCID: PMC4403466          DOI: 10.1128/JVI.00213-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  108 in total

Review 1.  Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C.

Authors:  C G Takizawa; D O Morgan
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

2.  E4orf3 is necessary for enhanced S-phase replication of cell cycle-restricted subgroup C adenoviruses.

Authors:  Robin N Shepard; David A Ornelles
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Distinct requirements of adenovirus E1b55K protein for degradation of cellular substrates.

Authors:  Rachel A Schwartz; Seema S Lakdawala; Heather D Eshleman; Matthew R Russell; Christian T Carson; Matthew D Weitzman
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

Review 4.  ATR signalling: more than meeting at the fork.

Authors:  Edward A Nam; David Cortez
Journal:  Biochem J       Date:  2011-06-15       Impact factor: 3.857

5.  Adenovirus type 5 early region 1B 55K oncoprotein-dependent degradation of cellular factor Daxx is required for efficient transformation of primary rodent cells.

Authors:  Sabrina Schreiner; Peter Wimmer; Peter Groitl; Shuen-Yuan Chen; Paola Blanchette; Philip E Branton; Thomas Dobner
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

6.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

7.  A 49-kilodalton isoform of the adenovirus type 5 early region 1B 55-kilodalton protein is sufficient to support virus replication.

Authors:  Kathrin Kindsmüller; Sabrina Schreiner; Florian Leinenkugel; Peter Groitl; Elisabeth Kremmer; Thomas Dobner
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

8.  Cell cycle-dependent subcellular translocation of the human DNA licensing inhibitor geminin.

Authors:  Maria Dimaki; Georgia Xouri; Ioanna-Eleni Symeonidou; Chaido Sirinian; Hideo Nishitani; Stavros Taraviras; Zoi Lygerou
Journal:  J Biol Chem       Date:  2013-06-29       Impact factor: 5.157

9.  SPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection.

Authors:  Sabrina Schreiner; Sarah Kinkley; Carolin Bürck; Andreas Mund; Peter Wimmer; Tobias Schubert; Peter Groitl; Hans Will; Thomas Dobner
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

10.  p53 induces transcriptional and translational programs to suppress cell proliferation and growth.

Authors:  Fabricio Loayza-Puch; Jarno Drost; Koos Rooijers; Rui Lopes; Ran Elkon; Reuven Agami
Journal:  Genome Biol       Date:  2013-04-17       Impact factor: 13.583

View more
  3 in total

1.  Normal human cell proteins that interact with the adenovirus type 5 E1B 55kDa protein.

Authors:  George Hung; S J Flint
Journal:  Virology       Date:  2017-01-27       Impact factor: 3.616

2.  A viral histone-like protein exploits antagonism between linker histones and HMGB proteins to obstruct the cell cycle.

Authors:  Kelsey L Lynch; Melanie R Dillon; Mongoljin Bat-Erdene; Hannah C Lewis; Robin J Kaai; Edward A Arnold; Daphne C Avgousti
Journal:  Curr Biol       Date:  2021-10-18       Impact factor: 10.834

3.  An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced.

Authors:  Takao Morinaga; Thảo Thi Thanh Nguyễn; Boya Zhong; Michiko Hanazono; Masato Shingyoji; Ikuo Sekine; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  Virol J       Date:  2017-11-10       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.